Kiniksa Pharmaceuticals International (KNSA) drew fresh attention after it raised its 2026 net product revenue guidance to US$980 million to US$995 million, following second quarter results and a company pipeline update.

Kiniksa Pharmaceuticals International’s recent guidance hike and strong second quarter results have come after a powerful run, with a year to date share price return of 76.98% and a 1 year total shareholder return of 132.46%. Despite a 1 day share price decline of 4.94%, momentum over the past 3 months and 5 years, reflected in a 34.50% 90 day share price return and a 466.18% 5 year total shareholder return, points to investors reassessing both growth potential and risk around the stock.

If you are looking beyond Kiniksa Pharmaceuticals International for other health related opportunities, this is a useful moment to review leading healthcare AI stocks using the 41 healthcare AI stocks

After Kiniksa Pharmaceuticals International’s sharp move and higher 2026 revenue guidance, the question is whether to accept today’s price or hold out for a pullback. How does the current valuation stack up against the fundamentals?

Most Popular Narrative: 6% Overvalued

The most followed narrative pegs Kiniksa Pharmaceuticals International's fair value at $70 against a last close of $74.34, so the stock screens slightly above that narrative estimate. The gap is not extreme, which puts more focus on what is driving that fair value than on the difference itself.

Significant expansion opportunities for ARCALYST remain, as market penetration into the recurrent pericarditis population is still only 15%, with a large additional segment (first recurrence patients) representing another untapped 26,000 patients. This is likely to continue to accelerate topline revenue growth as adoption widens across a growing addressable market due to population aging and rising prevalence of autoimmune/inflammatory disorders.

Want to understand why this relatively modest fair value premium still relies on ambitious growth assumptions and richer future profit margins. The narrative leans heavily on expanding the ARCALYST patient pool and higher earnings power several years out. Curious which revenue and margin bridges have to hold up for that to work.

Result: Fair Value of $70 (OVERVALUED)

However, Kiniksa Pharmaceuticals International still leans heavily on ARCALYST and a concentrated U.S. market, so any slowdown in uptake or tougher reimbursement decisions could quickly test that fair value story.

Another View On Kiniksa Pharmaceuticals International’s Valuation

While the most popular narrative sees Kiniksa Pharmaceuticals International as about 6% overvalued at $74.34 versus a $70 fair value, the SWS DCF model points in a very different direction. It suggests the stock trades well below an estimated future cash flow value of $352.27. That is a wide gap for you to reconcile.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kiniksa Pharmaceuticals International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals on Kiniksa Pharmaceuticals International leave you unsure, it may help to take a closer look at the underlying drivers and form your own view promptly. To see what investors are currently optimistic about in the thesis, review the 4 key rewards.

Looking For More Investment Ideas Beyond Kiniksa Pharmaceuticals International?

If you want to put what you have learned from Kiniksa Pharmaceuticals International to work, use these focused stock ideas now before the next move passes you by.

• Target stability and income by reviewing companies labelled as 9 dividend fortresses that aim to combine meaningful yields with resilience.
• Hunt for potential value opportunities by scanning 55 high quality undervalued stocks that may trade below estimates of their underlying quality.
• Prioritise resilience under pressure by zeroing in on 81 resilient stocks with low risk scores that show lower overall risk scores than the broader market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.